317 related articles for article (PubMed ID: 19562254)
1. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Friedman AH; Herndon JE; Marcello J; Norfleet JA; McLendon RE; Sampson JH; Friedman HS
J Neurooncol; 2010 Jan; 96(2):219-30. PubMed ID: 19562254
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Sathornsumetee S; Desjardins A; Vredenburgh JJ; McLendon RE; Marcello J; Herndon JE; Mathe A; Hamilton M; Rich JN; Norfleet JA; Gururangan S; Friedman HS; Reardon DA
Neuro Oncol; 2010 Dec; 12(12):1300-10. PubMed ID: 20716591
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.
Yung WK; Vredenburgh JJ; Cloughesy TF; Nghiemphu P; Klencke B; Gilbert MR; Reardon DA; Prados MD
Neuro Oncol; 2010 Oct; 12(10):1061-70. PubMed ID: 20615922
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
van den Bent MJ; Brandes AA; Rampling R; Kouwenhoven MC; Kros JM; Carpentier AF; Clement PM; Frenay M; Campone M; Baurain JF; Armand JP; Taphoorn MJ; Tosoni A; Kletzl H; Klughammer B; Lacombe D; Gorlia T
J Clin Oncol; 2009 Mar; 27(8):1268-74. PubMed ID: 19204207
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.
de Groot JF; Gilbert MR; Aldape K; Hess KR; Hanna TA; Ictech S; Groves MD; Conrad C; Colman H; Puduvalli VK; Levin V; Yung WK
J Neurooncol; 2008 Oct; 90(1):89-97. PubMed ID: 18581057
[TBL] [Abstract][Full Text] [Related]
6. A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R
Lung Cancer; 2017 Jun; 108():154-160. PubMed ID: 28625629
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Wen PY; Chang SM; Lamborn KR; Kuhn JG; Norden AD; Cloughesy TF; Robins HI; Lieberman FS; Gilbert MR; Mehta MP; Drappatz J; Groves MD; Santagata S; Ligon AH; Yung WK; Wright JJ; Dancey J; Aldape KD; Prados MD; Ligon KL
Neuro Oncol; 2014 Apr; 16(4):567-78. PubMed ID: 24470557
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh JJ; Gururangan S; Friedman AH; Desjardins A; Sathornsumetee S; Herndon JE; Dowell JM; McLendon RE; Provenzale JM; Sampson JH; Smith RP; Swaisland AJ; Ochs JS; Lyons P; Tourt-Uhlig S; Bigner DD; Friedman HS; Rich JN
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):860-8. PubMed ID: 16467100
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Peereboom DM; Shepard DR; Ahluwalia MS; Brewer CJ; Agarwal N; Stevens GH; Suh JH; Toms SA; Vogelbaum MA; Weil RJ; Elson P; Barnett GH
J Neurooncol; 2010 May; 98(1):93-9. PubMed ID: 19960228
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
Javle MM; Shroff RT; Xiong H; Varadhachary GA; Fogelman D; Reddy SA; Davis D; Zhang Y; Wolff RA; Abbruzzese JL
BMC Cancer; 2010 Jul; 10():368. PubMed ID: 20630061
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KA; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD;
Neuro Oncol; 2010 Jan; 12(1):95-103. PubMed ID: 20150372
[TBL] [Abstract][Full Text] [Related]
13. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.
Chheda MG; Wen PY; Hochberg FH; Chi AS; Drappatz J; Eichler AF; Yang D; Beroukhim R; Norden AD; Gerstner ER; Betensky RA; Batchelor TT
J Neurooncol; 2015 Feb; 121(3):627-34. PubMed ID: 25503302
[TBL] [Abstract][Full Text] [Related]
14. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Prados MD; Chang SM; Butowski N; DeBoer R; Parvataneni R; Carliner H; Kabuubi P; Ayers-Ringler J; Rabbitt J; Page M; Fedoroff A; Sneed PK; Berger MS; McDermott MW; Parsa AT; Vandenberg S; James CD; Lamborn KR; Stokoe D; Haas-Kogan DA
J Clin Oncol; 2009 Feb; 27(4):579-84. PubMed ID: 19075262
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
Galanis E; Buckner JC; Maurer MJ; Kreisberg JI; Ballman K; Boni J; Peralba JM; Jenkins RB; Dakhil SR; Morton RF; Jaeckle KA; Scheithauer BW; Dancey J; Hidalgo M; Walsh DJ;
J Clin Oncol; 2005 Aug; 23(23):5294-304. PubMed ID: 15998902
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Reardon DA; Vredenburgh JJ; Desjardins A; Peters KB; Sathornsumetee S; Threatt S; Sampson JH; Herndon JE; Coan A; McSherry F; Rich JN; McLendon RE; Zhang S; Friedman HS
J Neurooncol; 2012 Jul; 108(3):499-506. PubMed ID: 22407177
[TBL] [Abstract][Full Text] [Related]
18. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Gridelli C; Rossi A; Ciardiello F; De Marinis F; Crinò L; Morabito A; Morgillo F; Montanino A; Daniele G; Piccirillo MC; Normanno N; Gallo C; Perrone F
Clin Lung Cancer; 2016 Sep; 17(5):461-465. PubMed ID: 27209164
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
